Published in Medical Letter on the CDC and FDA, August 13th, 2006
A pharmacy benefit administrator (PBA), HealthTrans attributes this growth in part to successfully implementing plan benefit designs that advocate value-based formularies focusing on most cost-efficacious therapies, which in many cases fall to generic and even over the counter alternatives.
Stronger generic utilization typically provides for greater cost efficiencies in a transparent business model, because the drugs can be procured at much more aggressive rates and transparent relationships do not allow for mark-up pricing, so the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.